March enforcement wave accelerates the shift away from compounded GLP-1s
FDA released 30 warning letters to telehealth and compounding sellers on March 3, and Hims settled with Novo Nordisk days later, narrowing where compounded semaglutide can legally come from.
Two events in the first two weeks of March 2026 reshaped the market for compounded GLP-1 drugs. On March 3, the FDA publicly released 30 warning letters to telehealth companies and online wellness clinics accused of making false or misleading claims about compounded versions of GLP-1 medications [2]. Six days later, on March 9, Novo Nordisk and Hims & Hers announced a partnership under which Hims will sell branded semaglutide on its platform and stop advertising compounded alternatives [2].
What the warning letters said
The letters were signed on February 20, 2026 by Matthew J. Lash, acting director of the Office of Compounding Quality and Compliance within FDA's Center for Drug Evaluation and Research, and made public on March 3 [2]. They allege violations of Sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act, which bar false or misleading drug labeling and advertising [2].
According to the FDA, companies implied their compounded products were equivalent to or interchangeable with approved brands, using language such as "the same ingredients" as branded products or claims that the products had been "tested in clinical trials" [2]. Some also obscured the fact that the product was compounded, or failed to disclose where the compounded drug came from [2]. Recipients had 15 working days to respond with corrective steps, including identifying their compounding sources and removing misleading website claims; those who do not respond face possible "seizure and injunction" [2].
FDA Commissioner Marty Makary said of the release: "It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action" [2].
Sources differ on the size of the wave. Frier Levitt, writing on March 9, describes 30 letters [2]. A later industry summary describes more than 50 letters issued in March 2026 [1]. The 30-letter figure is tied to a specific, dated FDA release [2].
The Hims settlement
Under the March 9 agreement, Hims & Hers will offer Novo Nordisk's branded semaglutide products, Ozempic and Wegovy, and will cease advertising and marketing compounded GLP-1 drugs except where medically necessary [2]. Novo Nordisk dismissed its patent infringement lawsuit against Hims but reserved the right to refile [2]. Makary publicly endorsed the deal [2].
The backdrop: earlier in 2026, Hims said it planned to market a compounded version of Novo's oral semaglutide, and Makary pledged "swift action" against "illegal copycat drugs" before Hims backed off [2]. The FDA had already sent roughly 100 cease-and-desist letters over direct-to-consumer compounded drug ads in September 2025 [2].
Why it matters for patients
Compounded semaglutide has typically cost patients $150 to $400 a month, against $935 to $1,349 a month for brand-name Ozempic or Wegovy without insurance [1]. That gap is why millions used compounded versions, and why the enforcement shift hits wallets directly.
The legal basis for mass compounding ended when FDA declared the semaglutide shortage resolved in February 2025, with cutoffs of April 22, 2025 for 503A state-licensed pharmacies and May 22, 2025 for 503B outsourcing facilities to stop making copies [1]. Industry analysts now describe the 503B route as effectively closing, leaving patient-specific compounding at 503A pharmacies as the remaining path [1]. That route requires documented clinical need, such as an allergy to an inactive ingredient or a dosage form not commercially available; cost alone is not a recognized basis [1].
Safety was part of the rationale. As of April 30, 2025, FDA had received 520 adverse event reports tied to compounded semaglutide [1]. Reported problems include patients taking 5 to 20 times their intended dose because of confusion between "units" and mg/mL concentrations in multi-dose vials [1]. Only semaglutide base is FDA-approved; salt forms such as semaglutide sodium and semaglutide acetate are not [1].
Not everyone agrees with FDA's approach. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said he was "puzzled" by Makary's framing and noted the Supreme Court has held that "lawful pharmacies cannot be broadly prohibited from communicating truthful information about their services" [2].
What happens next
On April 1, 2026, FDA issued a policy clarification on compounding exemptions that legal analysts say does not carry the force of law but signals enforcement intent [1]. On April 30, 2026, the agency formally proposed removing semaglutide and tirzepatide from the 503B Bulk Drug Substances List, with comments open through June 29, 2026 [1]. Analysts expect a final rule in the third quarter of 2026, though the outcome is not yet decided [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.